Pre-op MRI of margins predicts rectal cancer survival

This article originally appeared here.
Pre-Op MRI of Margins Predicts Rectal Cancer Outcomes
Pre-Op MRI of Margins Predicts Rectal Cancer Outcomes

(HealthDay News) -- Preoperative high-resolution magnetic resonance imaging (MRI) assessment of circumferential resection margin (CRM) status predicts survival and other disease progression outcomes in patients with rectal cancer, according to a study published online Nov. 25 in the Journal of Clinical Oncology.

Fiona G.M. Taylor, from Mayday University Hospital in Croydon, U.K., and colleagues conducted a follow-up study in 374 patients with rectal cancer. Preoperative high-resolution pelvic MRIs were used to assess CRM, and the relationship of MRI assessment and outcomes were evaluated.

The researchers found that five-year overall survival (OS) was 62.2 percent in patients with MRI-clear CRM compared to 42.2 percent in patients with MRI-involved CRM (hazard ratio, 1.97). Disease-free survival (DFS) at five years was 67.2 percent for MRI-clear CRM versus 47.3 percent for MRI-involved CRM (hazard ratio, 1.65). For MRI-involved CRM, local recurrence (LR) was 3.50. In multivariate analysis, MRI-involved CRM was the only preoperative staging parameter that remained significant for OS, DFS, and LR.

"High-resolution MRI preoperative assessment of CRM status is superior to American Joint Committee on Cancer TNM-based criteria for assessing risk of LR, DFS, and OS," the authors write.

Full Text (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs